Cationic lipid:pDNA complexes for the treatment of cystic fibrosis

Current Opinion in Molecular Therapeutics

Volumn 1, Issue 2, 1999, Pages 186-196

  Eastman, Simon J ^a   Scheule, Ronald K ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORIDE CHANNEL; DNA; LIPOSOME; TRANSMEMBRANE CONDUCTANCE REGULATOR;

APICAL MEMBRANE; ARTICLE; CLINICAL TRIAL; CYSTIC FIBROSIS; EPITHELIUM CELL; EXPRESSION VECTOR; GENE MUTATION; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; ION TRANSPORT; NOSE MUCOSA;

CATIONS; CLINICAL TRIALS; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DNA; GENE THERAPY; HUMANS; LIPIDS; NASAL MUCOSA;

EID: 0033042565     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (100)

1. Korst RJ, McElvaney NG, Chu C-S, Rosenfeld MA, Mastrangeli A, Hay J, Brody SL, Eissa NT, Danel C, Jaffe HA, Crystal G: Gene therapy for the respiratory manifestations of cystic fibrosis. Am J Respir Crit Care Med (1995) 151:S75-S87. An excellent review of the rationale for CF gene therapy.
2. Tizzano E, Buchwald M: CFTR expression and organ damage in cystic fibrosis. Ann Intern Med (1995) 123:305-308.
3. Welsh M, Smith A: Cystic fibrosis. Scientific American (1995):52-59. An excellent review on the pathology of CF and strategies for treatment
4. Tsui L-C: The cystic fibrosis transmembrane conductance regulator gene. Am J Respir Crit Care Med (1995) 151R:S47-S53.
5. Denning GM, Ostedgaard LS, Cheng SH, Smith AE, Welsh WJ: Localization of cystic fibrosis transmembrane conductance regulator in chloride secretory epithelia. J Clin Invest (1992) 89:339-349.
6. Mergey M, Lemnaouar M, Veissiere D, Perricaudet M, Gruenert D, Picard J, Capeau J, Brahimi-Horn M-C, Paul A: CFTR gene transfer corrects defective glycoconjugate secretion in human CF epithelial tracheal cells. Am J Physiol (1995) 269:L855-L864.
7. Pier GB, Grout M, Zaidi TS: Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung. Proc Natl Acad Sci USA (1997) 94:12088-12093.
8. Davies JC, Stern M, Dewar A, Caplen NJ, Munkonge FM, Pitt T, Sorgi F, Huang L, Bush A, Geddes DM, Alton EW: CFTR gene transfer reduces the binding of Pseudomonas aeruginosa to cystic fibrosis respiratory epithelium. Am J Respir Cell Mol Biol (1997) 16:657-663.
9. Smith JJ, Travis SM, Greenburg EP, Welsh MJ: Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid. Cell (1996) 85:229-236. First evidence that the salt imbalance in CF airways may result in the inactivation of an innate immune response.
10. Goldman MJ, Anderson GM, Stolzenberg ED, Kari UP, Zasloff M, Wilson JM: Human β-defensin-1 is a salt sensitive antibiotic in lung that is inactivated in cystic fibrosis. Cell (1997) 88:553-560. Identification of dafensins as the innate immune element inactivated in CF lungs.
11. Wine JJ: A sensitive defense: Salt and cystic fibrosis. Nat Med (1997) 3:494-495.
12. Knowles MR, Robinson JM, Wood RE, Pue CA, Mentz WM, Wager GC, Gatzy JT, Boucher RC: Ion composition of airway surface liquid of patients with cystic fibrosis as compared with normal and disease-control subjects. J Clin Invest (1997) 100:2588-2595.
13. Shak S, Capon DJ, Hellmiss R, Marsters SA, Baker CL: Recombinant human DNase I reduces viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA (1990) 87:9188-9192.
14. Aitken ML, Burke W, McDonald G, Shak S, Montgomery AB, Smith A: Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis: A Phase I study. J Am Med Assoc (1992) 267:1947-1951.
15. Hubbard RC, McElvaney NG, Birrer P, Shak S, Robinson WW, Joley C, Wu M, Chernick MS, Crystal RG: A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis. N Engl J Med (1992) 326:812-815.
16. Ramsey BW, Astley SJ, Aitken ML, Burke W, Colin AA, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Schidlow DV, Wilmott R, Wohl M, Meyerson L, Shak S, Fuchs H, Smith A: Efficacy and safety of short term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis. Am Rev Respir Dis (1993) 148:145-151.
17. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AE, Wohl M: Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary functions in patients with cystic fibrosis. N Engl J Med (1994) 331:637-642.
18. Hudson ME: Aerosolized dornase alfa (rhDNase) for therapy of cystic fibrosis. Am J Respir Crit Care Med (1995) 151:870-374.
19. Saiman L, Mehar F, Niu WW, Neu HC, Shaw KJ, Miller G, Prince A: Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin Infect Dis (1996) 23:532-537.
20. Touw DJ, Jacobs FA, Brimicombe RW, Heijerman HG, Bakker W, Briemer DD: Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis. Antimicrob Agents Chemother (1997) 41:184-187.
21. Eisenberg J, Pepe M, Williams-Warren J, Vasilev M, Montgomery AB, Smith AL, Ramsey BW: A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized Tobramycin Study Group. Chest (1997) 111:955-962.
22. Weisemann HG, Steinkamp G, Ratjen F, Bauemfeind A, Przyklenk B, Döring G, von der Hardt H: Placebo-controlled, double blind, randomized study of aerosolized tobramycin for early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Pediatr Pulmonol (1998) 25:88-92.
23. Cheng SH, Gregory RJ, Marshall J, Paul S, Souza DW, White GA, O'Riordan CR, Smith AE: Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell (1990) 63:827-834. First description of the CFTR trafficking defect which is responsible for the majority of CF.
24. Ward CL, Omura S, Kopito RR: Degradation of CFTR by the ubiquitin-proteasome pathway. Cell (1995) 83:121-127.
25. Jiang C, Fang SL, Xiao Y-F, O'Connor SP, Nadler SG, Lee DW, Jefferson DM, Kaplan JM, Smith AE, Cheng SH: Partial restoration of cAMP-stimulated CFTR chloride channel activity in Delta508 cells by deoxyspergualin. Am J Physiol (1998) 275:C171-C178.
26. Cheng SH, Fang SL, Zabner J, Marshall J, Piraino S, Schiavi SC, Jefferson DM, Welsh MJ, Smith AE: Functional activation of cystic fibrosis trafficking mutant delta F508-CFTR by overexpression. Am J Physiol (1995) 268:L615-L624.
27. Sato S, Ward CL, Krouse ME, Wine JJ, Kopito RR: Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. J Biol Chem (1996) 271:635-638.
28. Brown CR, Hong-Brown LQ, Biwersi J, Verkman AS, Welch WJ: Chemical chaperones correct the mutant phenotype of the delta F508 cystic fibrosis transmembrane conductance regulator protein. Cell Stress Chaperones (1996) 1:117-125.
29. Curiel D, Pilewski J, Albelda S: Gene therapy approaches for inherited and acquired lung diseases. Am J Respir Cell Mol Biol (1996) 14:1-18.
30. Wagner JA, Gardner P: Toward cystic fibrosis gene therapy. Annu Rev Med (1997) 48:203-216.
31. Caplen NJ, Alton EW, Middleton PG, Dorin JR, Stevenson BJ, Gao X, Durham SR, Jeffery PK, Hodson ME, Coutelle C, Huang L, Porteous D, Williamson R, Geddes D: Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat Med (1995) 1:39-46.
32. Gill DR, Southern KW, Mofford KA, Seddon T, Huang L, Sorgi F, Thomson A, MacVinish U, Ratcliff R, Bilton D, Lane DJ, Littlewood JM, Webb AK, Middleton PG, Colledge WH, Cuthbert AW, Evans MJ, Higgins CF, Hyde SC: A placebo-controlled study of liposome-mediated gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther (1997) 4:199-209.
33. Porteous DJ, Dorin JR, McLachlan G, Davidson-Smith H, Davidson H, Stevenson BJ, Carothers AD, Wallace WA, Moralee S, Hoenes C, Kallmeyer G, Michaelis U, Naujoks K, Ho L-P, Samways JM, Imrie M, Greening AP, Innes JA: Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther (1997) 4:210-218.
34. Zabner J, Cheng SH, Meeker D, Launspach J, Balfour R, Perricone MA, Morris JE, Marshall J, Fasbender A, Smith AE, Welsh MJ: Comparison of DNA-lipid complexes and DNA alone for gene transfer to cystic fibrosis airway epithelia in vivo. J Clin Invest (1997) 100:1529-1537.
35. Knowles MR, Noone PG, Hohneker K, Johnson LG, Boucher RC, Efthimiou J, Crawford C, Brown R, Schwartzbach C, Pearlman R: A double-blind placebo controlled, dose ranging study to evaluate the safety and biological efficacy of the lipid-DNA complex GR213487B in the nasal epithelium of adult patients with cystic fibrosis. Hum Gene Ther (1998) 9:249-269.
36. Sorscher EJ, Logan JJ, Frizzell RA, Lyrene RK, Bebok Z, Dong JY, Duvall MD, Feigner PL, Matalon S, Walker L, Wiatrak B: Gene therapy for cystic fibrosis using cationic liposome mediated gene transfer: A phase I trial of safety and efficacy in the nasal airway. Hum Gene Ther (1994) 5:1259-1277.
37. Alton EW, Geddes DM: Gene therapy for cystic fibrosis: a clinical perspective. Gene Ther (1995) 2:88-95.
38. Boucher RC: Current status of CF gene therapy. Trends Genet (1996) 12:81-84.
39. Coutelle C: Gene therapy approaches for cystic fibrosis. Biologicals (1995) 23:21-25.
40. Middleton PG, Caplen NJ, Gao X, Huang L, Gaya H, Geddes DM, Alton EW: Nasal application of the cationic liposome DC-Chol:DOPE does not alter ion transport, lung function or bacterial growth. Eur Respir J (1994) 7:442-445.
41. Stern M, Munkonge FM, Caplen NJ, Sorgi F, Huang L, Geddes DM, Alton EW: Quantitative fluorescence measurements of chloride secretion in native airway epithelium from CF and non-CF subjects. Gene Ther (1995) 2:766-774.
42. McLachlan G, Ho L-P, Davidson-Smith H, Samways J, Davidson H, Stevenson BJ, Carothers AD, Alton EW, Middleton PG, Smith SN, Kallmeyer G, Michaelis U, Seeber S, Naujoks K, Greening AP, Innes JA, Dorin JR, Porteous DJ: Laboratory and clinical studies in support of cystic fibrosis gene therapy using pCMV-CFTR-DOTAP. Gene Ther (1996) 3:1113-1123.
43. Johnson LE, Olsen JC, Sarkadi B, Moore KL, Swanstrom R, Boucher RC: Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nat Genet (1992) 2:21-25.
44. Goldman MJ, Yang Y, Wilson JM: Gene therapy in a xenograft model of cystic fibrosis lung corrects chloride transport more effectively than the sodium defect Nat Genet (1995) 9:126-131.
45. Lee ER, Marshall J, Siegel CS, Jiang C, Yew NS, Nichols MR, Nietupski JB, Ziegler RJ, Lane MB, Wang KX, Wan NC, Scheule RK, Harris DJ, Smith AE, Cheng SH: Detailed analysis of structures and formulations of cationic lipids for efficient gene transfer to the lung. Hum Gene Ther (1996) 7:1701-1717.
46. Jiang C, O'Connor S, Fang S, Wang K, Marshall J, Williams J, Wilbum B, Echelard Y, Cheng S: Efficiency of cationic lipid-mediated transfection of polarized and differentiated airway epithelial cells in vitro and in vivo. Hum Gene Ther (1998) 9:1531-1542. Nicely demonstrates the nuclear membrane as a major barrier to cationic lipid-mediated transfection.
47. Logan JJ, Bebok Z, Walker LC, Peng S, Felgner PL, Siegal GP, Frizzell RA, Dong J, Howard M, Matalon S, Lindsey J, DuVall M, Sorscher E: Cationic lipids for reporter gene and CFTR transfer to rat pulmonary epithelium. Gene Ther (1995) 2:38-49.
48. Stribling R, Brunnette E, Liggitt D, Gaensler K, Debs R: Aerosol gene delivery in vivo. Proc Natl Acad Sci USA (1992) 89:11277-11281.
49. Alton EW, Middleton PG, Caplen NJ, Smith SN, Steel DM, Munkonge FM, Jeffrey PK, Geddes DM, Hart SL, Williamson R, Fasold K, Miller A, Dickinson P, Stevenson B, McLachlan G, Dorin J, Porteous D: Non-invasive liposome-mediated gene delivery can correct the ion transport defect in cystic fibrosis mutant mice. Nat Genet (1993) 5:135-142.
50. Canonico A, Conary J, Meyrick B, Brigham K: Aerosol and intravenous transfection of Human α1-antitrypsin gene to lungs of rabbits. Am J Respir Cell Mol Biol (1994) 10:24-29.
51. Eastman SJ, Tousignant JD, Lukason MJ, Murray H, Siegel CS, Constantino P, Harris DJ, Cheng SH, Scheule RK: Optimization of formulations and conditions for the aerosol delivery of functional cationic lipid:DNA complexes. Hum Gene Ther (1997) 8:313-322.
52. Eastman SJ, Lukason MJ, Tousignant JD, Murray H, Lane MD, St George JA, Akita GY, Cherry M, Cheng SH, Scheule RK: A concentrated and stable aerosol formulation of cationic lipid: DNA complexes giving high level gene expression in mouse lung. Hum Gene Ther (1997) 8:765-773. Describes methods for measuring transfer of both the lipid and DNA components of complexes via an aerosol and methods for preparing formulations at extremely high concentrations.
53. Crook K, McLachlan G, Stevenson BJ, Porteous DJ: Plasmid DNA molecules completed with cationic liposomes are protected from degradation by nucleases and shearing by aerosolizatlon. Gene Ther (1996) 3:834-839.
54. Stern M, Sorgi F, Hughes C, Caplen N, Browning J, Middleton P, Gruenert D, Farr S, Huang L, Geddes D, Alton E: The effects of jet nebulisation on cationic liposome-mediated gene transfer in vitro. Gene Ther (1998) 5:583-593.
55. Scheule RK, St George JA, Bagley RG, Marshall J, Kaplan JM, Akita GY, Wang KX, Lee ER, Harris DJ, Jiang C, Yew NS, Smith AE, Cheng SH: Basis of pulmonary toxicity associated with cationic lipid-mediated gene transfer to the mammalian lung. Hum Gene Ther (1997) 8:689-707. Describes the potential toxicities associated with high doses of cationic lipids.
56. McDonald RJ, Liggitt HD, Roche L, Nguyen HT, Pearlman R, Raabe OG, Bussey LB, German CM: Aerosol delivery of lipid:DNA complexes to lungs of rhesus monkeys. Pharm Res (1998) 15:671-679. Describes successful delivery of a transgene to the airways of a non-human primate employing an aerosolized cationic lipid:pDNA complex.
57. Gorman CM, Aikawa M, Fox B, Fox E, Lapuz C, Michaud B, Nguyen H, Roche E, Sawa T, Wiener-Kronish JP: Efficient in vivo delivery of DNA to pulmonary cells using the novel lipid EDMPC. Gene Ther (1997) 4:983-992. Describes a lipid with high efficacy and low toxicity in the lung. This lipid is very similar to naturally occurring phospholipids and is potentially more biodegradable than most other cationic lipids.
58. Eastman SJ, Tousignant JD, Lukason MJ, Chu Q, Cheng SH, Scheule RK: Aerosolization of cationic lipid:pDNA complexes - in vitro optimization of nebulizer parameters for human clinical studies. Hum Gene Ther (1998) 9:43-52. Describes nebulizer parameters for use in delivering cationic lipid:pDNA complexes to the lungs of human subjects.
59. 5000 formulation to the lungs of normal volunteers. Gene Ther (1997) 4:937-942.
60. Alton EW, Geddes DM, Gill DR, Higgins CF, Hyde SC, Innes JA, Porteous DJ: Towards gene therapy for cystic fibrosis: a clinical progress report Gene Ther (1998) 5:291-292.
61. Alton EW, Stern M, Farley R, Jaffe A, Chadwick SL, Philips J, Davies J, Smith SN, Browning J, Davies MG, Hodson ME, Durham SR, Li D, Jeffery PK, Scallan M, Balfour R, Eastman SJ, Cheng SH, Smith AE, Meeker D, Geddes DM: Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. The Lancet (1999) 353: 947-954. First clinical trial of aerosolized cationic lipid:pDNA complexes, describes a clinical syndrome associated with the delivery of cationic lipid:pDNA complexes to the lungs of CF patients.
62. Ruiz F: Gene transfer of CFTR to lower airways of cystic fibrosis patients and description of a clinical syndrome attributable to lipid/DNA administration. Ped Pulm (1998) 17:266.
63. Wloch MK, Pasquini S, Ertl HC, Pisetsky DS: The influence of DNA sequence on the immunostimulatory properties of plasmid DNA vectors. Hum Gene Ther (1998) 9:1439-1447.
64. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature (1995) 374:546-549. Offers possible explanation for the clinical syndrome observed after aerosolization of cationic lipid:pDNA complexes into the lungs of CF subjects.
65. Krieg AM: Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA. Trends Microbiol (1995) 4:73-76. Offers possible explanation for the clinical syndrome observed after aerosolization of cationic lipid:pDNA complexes into the lungs of CF subjects.
66. Klinman DM, Yi AK, Beaucage SL, Conover J, Krieg AM: CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin-6, interleukin-12, and interferon-gamma. Proc Natl Acad Sci USA (1996) 83:2879-2883. Offers possible explanation for the cliniacl sydrome observed after aerosolization of cationic lipid:pDNA complexes into the lungs of CF subjects.
67. Pisetsky DS: Immune activation by bacterial DNA: A new genetic code. Immunity (1996) 5:303-310.
68. Freimark BD, Blezinger HP, Florack VJ, Nordstrom JL, Long SD, Deshpande DS, Nochumson SA, Petrak KL: Cationic lipids enhance cytokine and cell influx levels in the lung following administration of plasmid: cationic lipid complexes. J Immunol (1998) 160:4580-4586. First paper indicating that cationic lipids enhance the immunostimulatory effects of bacterially derived DNA and that the production of cytokines is a result of the DNA origin and not the presence of endotoxins.
69. Yew N, Wang K, Przybylska M, Bagley R, Stedman M, Marshall J, Scheule RK, Cheng SH: Contribution of plasmid DNA to inflammation in the lung following administration of cationic lipid:pDNA complexes. Hum Gene Ther (1999) 10:223-234.
70. Ferrai MG, Nguyen CM, Zelphati O, Tsai Y, Feigner PL: Analytical methods for the characterization of cationic lipid-nucleic acid complexes. Hum Gene Ther (1998) 9:341-351.
71. Harvie P, Wong FM, Bally MB: Characterization of lipid DNA interactions. I. Destabilization of bound lipids and DNA dissociation. Biophys J (1998) 75:1040-1051.
72. Häcker H, Mischak H, Miethke T, Uptay S, Schmid R, Sparwasser T, Heeg K, Lipford G, Wagner H: CpG-DNA specific activation of antigen presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J (1998) 17:6230-6240. Provides a potential explanation of why cationic lipids may enhance the immunostimulatory effects of CpG sequences as cationic lipids tend to be taken into cells via endocytic pathways.
73. Bonfield TL, Panuska JR, Konstan MW, Hilliard KA, Hilliard JB, Ghnaim H, Berger M: Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med (1995) 152:2111-2118.
74. Griese M, Birrer P, Demirsoy A: Pulmonary surfactant in cystic fibrosis. Eur Respir J (1997) 10:1983-1988.
75. Witko-Sarsat V, Delacourt C, Rabier D, Bardet J, Nguyen AT, Descamps-Latscha B: Neutrophil-derived long-lived oxldants in cystic fibrosis sputum. Am J Respir Crit Care Med (1995) 152:1910-1916.
76. Chu Q, Tousignant J, Fang S, Jiang C, Chen L, Cheng S, Scheule R, Eastman S: Binding and uptake of cationic lipid:pDNA complexes by polarized epithelial cells. Hum Gene Ther (1999) 10:25-36. Describes an assay for distinguishing between cationic lipid:pDNA complexes bound to the surface or internalized by cells and further examines the barriers to uptake of cationic lipid:pDNA complexes by polarized cells.
77. Fasbender AJ, Zabner J, Welsh MJ: Optimization of cationic lipid-mediated gene transfer to airway epithelia. Am J Physiol (1995) 269:L45-L51.
78. Zabner J, Fasbender AJ, Moninger T, Poellinger KA, Welsh MJ: Cellular and molecular barriers to gene transfer by a cationic lipid. J Biol Chem (1995) 270:18997-19007.
79. Matsui H, Johnson LG, Randell SH, Boucher RC: Loss of binding and entry of liposome-DNA complexes decreases transfection efficiency in differentiated airway epithelial cells. J Biol Chem (1997) 272:1117-1126. Describes the apical membrane of differentiated airway epithelial cells as a significant barrier to cationic lipid-mediated transfection and examines the reasons for the differences in transfection efficiency of cells at different stages of differentiation.
80. Fasbender A, Zabner J, Zeiher BG, Welsh MJ: A low rate of cell proliferation and reduced DNA uptake limit cationic lipid-mediated gene transfer to primary cultures of ciliated human airway epithelia. Gene Ther (1997) 4:1173-1180.
81. Duan D, Yue Y, Yan Z, McCray P, Englehardt J: Polarity influences the efficiency of recombinant adenoassociated virus infection in differentiated airway epithelia. Hum Gene Ther (1998) 9:2761-2776. A very clear example of the differences in membrane activity between the basal and apical membranes of polarized airway epithelial cells.
82. Pickles RJ, McCarty D, Matsui H, Hart PJ, Randell SH, Boucher RC: Limited entry of adenovirus vectors into well-differentated airway epithelium is responsible for inefficient gene transfer. J Virol (1998) 72:6014-6023. Shows that adenovirus has similar problems as cationic lipid:pDNA complexes with regards to entry into differentiated airway epithelial cells.
83. Dowty M, Williams P, Zhang G, Hagstrom J, Wolff J: Plasmid DNA entry into postmitotic nuclei of primary rat myotubules. Proc Natl Acad Sci USA (1995) 92:4572-4576.
84. Wilke M, Fortunati E, van den Broek M, Hoogeveen AT, Scholte BJ: Efficay of a peptide-based gene delivery system depends on mitotic activity. Gene Ther (1996) 3:1133-1142. A nice study showing the effects of mitosis on the efficiency of non-viral gene therapy vectors.
85. Parsons D, Grubb B, Johnson L, Boucher R: Enhanced in vivo gene transfer via transient modification of host barrier properties with a surface-active agent Hum Gene Ther (1998) 9:2661-2672. First in vivo demonstration that tight junction disrupters can improve gene transfer to nasal airways.
86. Stern M, Caplen NJ, Browning JE, Griesenbach U, Sorgi F, Huang L, Gruenert DC, Marriot C, Crystal RG, Geddes DM, Alton EW: The effect of mucolytic agents on gene transfer across a CF sputum barrier in vitro. Gene Ther (1998) 5:91-98.
87. Guillaume-Gable C, Roch V, Mercier B, Audrézet M, Le Bloc'H G, Yaouanc J, Clément J, Des Abbayes H, Leroy J, Morin V, Férec C: Cationic phosphonolipids as nonviral gene transfer agents in the lungs of mice. Hum Gene Ther (1998) 9:2309-2319.
88. McCluskie M, Chu Y, Xia J, Jessee J, Gebyehu G, Davis H: Direct gene transfer to the respiratory tract of mice with pure plasmld and lipid-formulated DNA. Antisense Nucleic Acid Drug Dev (1998) 8:401-414.
89. Oudrhiri N, Vigneron JP, Pleuchmaur M, Leclerc T, Lehn JM, Lehn P: Gene transfer by guanidium-cholesterol cationic lipids into airway epithelial cells in vitro and in vivo. Proc Nat J Acad Sci USA (1997) 94:1651-1656.
90. Huang C, Uno T, Murphy J, Lee S, Hamer J, Escobedo J, Cohen F, Radkakrishnan R, Dwarki V, Zuckermann R: Lipitoids - novel cationic lipids for cellular delivery of plasmid DNA in vitro. Chem Biol (1998) 5:345-354
91. Aberle A, Tablin F, Zhu J. Walker N, Gruenert D, Nantz M: A novel tetraester construct that reduces cationic lipid-associated cytotoxicity. Implications for the onset of cytotoxicity. Biochemistry (1998) 37:6533-6540.
92. Wang J, Guo X, Xu Y, Barron L, Szoka FC: Synthesis and characterization of long chain alkyl acyl carnitine esters. Potentially biodegradable cationic lipids for use in gene delivery. J Med Chem (1998) 41:2207-2215.
93. Colin M, Harbottle R, Knight A, Komprobst M, Cooper R, Miller A, Trugnan G, Capeau J, Coutelle C, Brahimi-Hom M: Liposomes enhance delivery and expression of an RGD-oligolysine gene transfer vector in human tracheal cells. Gene Ther (1998) 5:1488-1498.
94. Saeki Y, Matsumoto N, Nakano Y, Mori M, Awai K, Kaneda Y: Development and characterization of cationic liposomes conjugated with HVJ (Sendai virus): Reciprocal effect of cationic lipid for in vitro and in vivo gene transfer. Hum Gene Ther (1997) 8:2133-2141.
95. Yonemitsu, Kaneda Y, Muraishi A, Yoshizumi T, Sugimachi, Sueishi K: HVJ (Sendai virus)-cationic liposomes: a novel and potentially effective liposome-mediated technique for gene transfer to the airway epithelium. Gene Ther (1997) 4:631-638.
96. Waelti E, Glück R: Delivery to cancer cells of antisense L-myc oligonucleotides incorporated in fusogenic, cationic-lipid-reconstituted influenza-virus envelopes (cationic virosomes). Int J Cancer (1998) 77:728-733.
97. Coonrod A, Li F-Q, Horwitz M: On the mechanism of DNA transfection: efficient gene transfer without viruses. Gene Ther (1997) 4:1313-1321.
98. Pollard H, Remy J-S, Loussouam G, Demolombe S, Behr J-P, Escande O: Polyethyleneimine but not cationic lipids promotes transgene delivery to the nucleus in mammalian cells. J Biol Chem (1998) 273:7507-7511.
99. Collas P, Aleström P: Rapid targeting of plasmid DNA to zebrafish embryo nuclei by the nuclear localization signal of SV40 T antigen. Mol Mar Biol Biotechnol (1997) 6:48-58.
100. Sebestyén MG, Ludtke JJ, Bassik MC, Zhang G, Budker V, Lukhtanov EA, Hagstrom JE, Wolff JA: DNA vector chemistry: The covalent attachment of signal peptides to plasmid DNA. Nat Biotechnol (1998) 16:80-85.